Welcome to our dedicated page for Abbott Labs SEC filings (Ticker: ABT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Abbott Laboratories (NYSE: ABT), an Illinois-incorporated healthcare company whose common shares are listed on the New York Stock Exchange. Through these filings, investors can review official disclosures on Abbott’s operations, governance, financial reporting practices and material corporate events.
Abbott’s SEC filings include periodic reports and current reports on Form 8-K. Recent 8-K filings describe matters such as the entry into an Agreement and Plan of Merger with Exact Sciences Corporation, under which a wholly owned Abbott subsidiary will merge with Exact Sciences, with Exact Sciences surviving as a direct, wholly owned subsidiary of Abbott subject to customary closing conditions. Another 8-K details a notice of a blackout period for certain employee benefit plans due to administrative changes, including recordkeeper, trustee and custodian transitions, and outlines related trading restrictions for directors and executive officers. Additional 8-K disclosures cover corporate governance updates, such as amendments to Abbott’s by-laws to change the size of the board of directors and the appointment of a new director, as well as announcements of quarterly financial results and the company’s use of non-GAAP financial measures.
On Stock Titan, each new Abbott filing from the SEC’s EDGAR system can be viewed alongside AI-powered summaries that explain key points in clear language. These summaries help readers quickly understand topics like merger terms, benefit plan blackout periods, board changes, or how management presents adjusted financial metrics, without having to parse every technical detail. Users can also review exhibits referenced in the filings, such as merger agreements, notices to directors and officers, and amended by-laws, to see the underlying legal documents.
For those tracking insider-related information, governance changes or major transactions, Abbott’s SEC filings offer an authoritative record of the company’s regulatory disclosures, while AI-generated insights on this page aim to make those documents more accessible and easier to interpret.
Abbott Laboratories executive Mary K. Moreland, an Executive Vice President, reported updated holdings of common shares. A discretionary transaction under Rule 16b-3(f) involved 5,314 common shares in a Profit Sharing Trust at $94.41 per share, leaving 17,159 shares held indirectly in the trust as of April 28, 2026. A separate holding entry shows 104,291 common shares held directly in her name. A footnote describes this as the balance in the Abbott Laboratories Stock Retirement Trust as of that date.
Abbott Laboratories shareholder disclosure: Vanguard Capital Management reports beneficial ownership of 130,676,776 shares of Abbott Laboratories common stock, representing 7.5% of the class as of the filing. The filing shows sole dispositive power over 130,676,776 shares and sole voting power for 17,726,843 shares. The form is signed on 04/29/2026.
Conroy Kevin T reported acquisition or exercise transactions in this Form 4 filing.
Abbott Laboratories director Kevin T. Conroy received a grant of 2,286 common shares in the form of restricted stock units. These units were awarded under the Abbott Laboratories 2026 Incentive Stock Program as compensation, not through an open-market purchase.
The award will be settled one-for-one in Abbott common shares upon the earlier of his separation from service, death, or a change in control as defined in the program. After this grant, Conroy directly holds 133,737 Abbott common shares.
ABBOTT LABORATORIES director Kevin T. Conroy filed an initial Form 3 reporting his equity stake following Abbott’s acquisition of Exact Sciences. He reports direct beneficial ownership of 131,451 common shares without par value. This position primarily reflects restricted stock units that accelerated upon Exact’s change in control at the merger’s effective time.
Under the merger completed on March 23, 2026, each share of Exact common stock was converted into the right to receive $105.00 in cash, without interest, subject to withholding taxes. Certain Exact restricted stock units were assumed by Abbott and converted into Abbott restricted stock unit awards based on the merger consideration and the 10‑day average Abbott share price. The reported RSU award fully accelerated at separation; one quarter was settled immediately, and the remaining three quarters will be settled in shares six months and one day after the effective time, with an option to have shares withheld for taxes.
Stratton John G reported acquisition or exercise transactions in this Form 4 filing.
Abbott Laboratories director John G. Stratton received an award covering 2,286 common shares as a grant of restricted stock units under the Abbott Laboratories 2026 Incentive Stock Program. Following this award, he holds 21,319 common shares directly.
The award will be settled in Abbott common shares on a one-to-one basis upon the earlier of the director’s separation from service, death, or a change in control as defined in the program. This is a compensation-related equity grant rather than an open-market share purchase.
ABBOTT LABORATORIES director Daniel J. Starks bought additional company stock and received new equity awards. He made an open-market purchase of 10,000 common shares at an average price of $92.6537 per share, bringing his direct holding to 6,751,103 common shares.
Starks also received a grant of 2,286 restricted stock units under Abbott’s 2026 Incentive Stock Program, payable one-for-one in common shares upon separation from service, death, or a change in control. In addition, he was granted stock options for 7,105 common shares at an exercise price of $91.86 per share, expiring in 2036. Separately, 258 common shares are held indirectly in the Alynne Starks 2012 Irrevocable Trust, for which he is the sole trustee.
ABBOTT LABORATORIES director Michael F. Roman received an equity award covering 2,286 common shares. The Form 4 shows this as a grant or award acquisition at a stated price of $0.00 per share, bringing his directly held stake to 10,764 common shares after the transaction.
The footnote explains this is a restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program. The units will convert one-for-one into Abbott common shares upon the earlier of his separation from service, death, or a change in control as defined in the program.
ABBOTT LABORATORIES director Michael O’Grady reported equity awards under the company’s 2026 Incentive Stock Program. He was granted 2,286 restricted stock units, each convertible into one Abbott common share upon separation from service, death, or a change in control as defined in the program.
He also received an option to buy 5,929 Abbott common shares at an exercise price of $91.86 per share, expiring on April 23, 2036, in a transaction exempt from Section 16 under Rule 16b-3. Following these awards, his direct holdings of Abbott common shares reported in this filing total 7,603 shares.
Abbott Laboratories director Nancy McKinstry reported equity awards rather than open-market trades. She received 2,286 restricted stock units that will convert one-for-one into common shares upon separation from service, death, or a change in control under Abbott’s 2026 Incentive Stock Program.
She also received options for 2,305 common shares at an exercise price of $91.86 per share, expiring in 2036. Following these awards, she directly holds 41,010 common shares and 2,305 options.